Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2010

View Archived Issues

GSK-1521498 reduces hedonistic eating behavior in overweight/obese subjects

Several phase II trials support safety and tolerability of BMS-708163 in healthy subjects

Sexual dysfunction in schizophrenia linked to typical antipsychotics, prolactin and DRD2 genotype

Scientists find new oncolytic virus sensitizers showing potential in cancer therapy

Astaxanthin derivatives show promise in preclinical models of cardiovascular inflammation

Intra-Cellular Therapies reports phase Ib/II data on ITI-007 in schizophrenia

Charles River Laboratories and WuXi PharmaTech terminate acquisition agreement

First patients with hepatitis C achieve SVR in phase II ANA-528 trial

Daiichi Sankyo and Kitasato Institute to form joint venture company

Harvard College claims new fluorinated compounds

New phase III pimavanserin trial begins in Parkinson's disease psychosis

German scientists discover new nitric oxide donors/arginase inhibitors

GlaxoSmithKline discloses new NS5B inhibitors

FDA lifts hold on Geron's IND application for GRNOPC1 ESC-based therapy

National Eye Institute awards Lpath grant to develop sonepcizumab for wet AMD

Auspex Pharma presents new deuterated clozapine derivatives

FDA advises of adverse effects related to unintended exposure to Evamist

Daiichi Sankyo discovers novel CaS receptor antagonists

Actient Pharmaceuticals acquires six pharmaceuticals from UCB

Update on Fluvax seasonal influenza vaccine

Abraxane is approved in New Zealand for metastatic breast cancer

Novartis begins phase I trial of HuCAL-derived antibody

Stellar Pharma and Inibsa sign agreement to distribute and sell Uracyst in Spain

Curaxis Pharmaceutical merges with Auto Search Cars

Icagen and Pfizer begin first-in-human trial in sodium channel program for pain

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026